Guggenheim Capital LLC Sells 186,308 Shares of Certara, Inc. (NASDAQ:CERT)

Guggenheim Capital LLC decreased its holdings in shares of Certara, Inc. (NASDAQ:CERT - Free Report) by 91.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 17,760 shares of the company's stock after selling 186,308 shares during the period. Guggenheim Capital LLC's holdings in Certara were worth $189,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in the business. Venturi Wealth Management LLC lifted its stake in Certara by 839.1% during the fourth quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company's stock valued at $30,000 after buying an additional 2,509 shares in the last quarter. Wells Fargo & Company MN lifted its stake in Certara by 48.4% during the fourth quarter. Wells Fargo & Company MN now owns 3,208 shares of the company's stock valued at $34,000 after buying an additional 1,047 shares in the last quarter. Blue Trust Inc. lifted its stake in Certara by 20.9% during the fourth quarter. Blue Trust Inc. now owns 4,747 shares of the company's stock valued at $56,000 after buying an additional 822 shares in the last quarter. ANTIPODES PARTNERS Ltd lifted its stake in Certara by 204.7% during the fourth quarter. ANTIPODES PARTNERS Ltd now owns 5,442 shares of the company's stock valued at $58,000 after buying an additional 3,656 shares in the last quarter. Finally, Sterling Capital Management LLC lifted its position in shares of Certara by 57.2% in the fourth quarter. Sterling Capital Management LLC now owns 7,209 shares of the company's stock worth $77,000 after purchasing an additional 2,624 shares in the last quarter. Institutional investors own 73.96% of the company's stock.

Certara Stock Down 4.1 %

NASDAQ:CERT traded down $0.57 during trading hours on Thursday, reaching $13.29. The company's stock had a trading volume of 2,537,458 shares, compared to its average volume of 1,237,805. The company has a market cap of $2.15 billion, a price-to-earnings ratio of -66.45, a price-to-earnings-growth ratio of 9.29 and a beta of 1.64. Certara, Inc. has a one year low of $8.64 and a one year high of $17.94. The business's 50-day moving average is $11.67 and its 200-day moving average is $11.62. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86.

Analysts Set New Price Targets

CERT has been the topic of several research reports. TD Cowen started coverage on shares of Certara in a research note on Thursday, February 27th. They issued a "buy" rating and a $16.00 price objective on the stock. Stephens restated an "overweight" rating and set a $17.00 price target on shares of Certara in a report on Thursday, February 27th. KeyCorp boosted their price target on shares of Certara from $15.00 to $18.00 and gave the company an "overweight" rating in a report on Wednesday, April 16th. William Blair restated a "market perform" rating on shares of Certara in a report on Thursday, February 27th. Finally, Barclays lowered their price target on shares of Certara from $13.00 to $11.00 and set an "equal weight" rating on the stock in a report on Thursday, April 10th. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $15.17.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.